Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing.

Harvard Business Review (HBR) named CSL Limited CEO and Managing Director Paul Perreault among the Top 100 Best Performing CEOs in the world for 2019.

Top 100 CEO rankings based on financial performance as well as environmental, social, and governance (ESG) ratings

CSL statement in response to media reports on case against Joseph Chiao

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at market open.

Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and cancer.

Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination